ReviewCurrent pain and headache reports2020
Neuropathic Pain and Sickle Cell Disease: a Review of Pharmacologic Management.
Review in Current pain and headache reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Data Quality Issues With Physician-Rating Websites: Systematic Review.Journal of medical Internet research · 2020Pooled it
- Decoding lactylation in neuropathic pain: Immune cell infiltration patterns and machine learning-identified candidate biomarkers.Medicine · 2026Article
- Association of depression and hydroxyurea use with neuropathic pain in hemoglobinopathies.Scientific reports · 2025Article
- Using Integrated Network Pharmacology and Metabolomics to Reveal the Mechanisms of the Combined Intervention of Ligustrazine and Sinomenine in CCI-Induced Neuropathic Pain Rats.International journal of molecular sciences · 2025Article
- GDF11 Mitigates Neuropathic Pain via Regulation of Microglial Polarization and Neuroinflammation through TGF-βR1/SMAD2/NF-κB Pathway in Male Mice.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Prediction and validation of anoikis-related genes in neuropathic pain using machine learning.PloS one · 2025Article
- Article
- Safety and efficacy of ketorolac continuous infusion for multimodal analgesia of vaso-occlusive crisis in patients with sickle cell disease.Orphanet journal of rare diseases · 2024Article
- Ligustrazine alleviates spinal cord injury-induced neuropathic pain by inhibiting the TLR4/NF-κB signaling pathway.American journal of translational research · 2024Article
- Paeonol alleviates neuropathic pain by modulating microglial M1 and M2 polarization via the RhoA/p38MAPK signaling pathway.CNS neuroscience & therapeutics · 2023Article
- Pharmacogenetics of pain management in Zimbabwean patients with sickle cell disease.Pharmacogenomics · 2023Article
- Identification of pyroptosis‑related genes in neuropathic pain based on bioinformatics analysis.Experimental and therapeutic medicine · 2023Article
- Prevalence of neuropathic pain in adolescents with sickle cell disease: A single-center experience.Pediatric blood & cancer · 2022Article
- Glycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components.Molecules (Basel, Switzerland) · 2021Review
- Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease.Journal of clinical medicine · 2020Review
- Mitochondrial dysfunction and disulfidptosis co-regulate neuronal cell in neuropathic pain based on bioinformatics analysis.Molecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSickle cell disease (SCD) remains among the most common and severe monogenic disorders present in the world today. Although sickle cell pain has been traditionally characterized as nociceptive, a significant portion of sickle cell patients has reported neuropathic pain symptoms. Our review article will discuss clinical aspects of SCD-related neuropathic pain, epidemiology of neuropathic pain among individuals with SCD, pain mechanisms, and current and future potential pharmacological interventions. RECENT
findingsNeuropathic pain in SCD is a complicated condition that often has a lifelong and significant negative impact on life; therefore, improved pain management is considered a significant and unmet need. Neuropathic pain mechanisms are heterogeneous, and the difficulty in determining their individual contribution to specific pain types may contribute to poor treatment outcomes in this population. Our review article outlines several pharmacological modalities which may be employed to treat neuropathic pain in SCD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.